Trevi Therapeutics Inc. (TRVI)
NASDAQ: TRVI
· Real-Time Price · USD
7.06
0.32 (4.75%)
At close: Jun 06, 2025, 3:59 PM
7.06
0.00%
After-hours: Jun 06, 2025, 05:43 PM EDT
Company Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.
The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.
The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics Inc.

Country | United States |
IPO Date | May 7, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 31 |
CEO | Jennifer L. Good |
Contact Details
Address: 195 Church Street New Haven, Connecticut United States | |
Website | https://www.trevitherapeutics.com |
Stock Details
Ticker Symbol | TRVI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001563880 |
CUSIP Number | 89532M101 |
ISIN Number | US89532M1018 |
Employer ID | 45-0834299 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jennifer L. Good | Co-Founder, Chief Executive Officer, President & Director |
Lisa Delfini | Chief Financial Officer |
Christopher Galletta | Controller & Chief Accounting Officer |
Dr. James V. Cassella Ph.D. | Chief Development Officer |
Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Scientific Officer |
Farrell Simon Pharm.D. | Chief Commercial Officer |
Katie McManus | Communications Manager |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 04, 2025 | 8-K | Current Report |
Jun 04, 2025 | 424B5 | Filing |
Jun 03, 2025 | 4 | Filing |
Jun 03, 2025 | 4 | Filing |
Jun 03, 2025 | 4 | Filing |
Jun 03, 2025 | 4 | Filing |
Jun 03, 2025 | 4 | Filing |
Jun 02, 2025 | 424B5 | Filing |
Jun 02, 2025 | 8-K | Current Report |
Jun 02, 2025 | 8-K | Current Report |